Flecainide
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Flecainide and local guidelines before prescribing.
Mechanism
Class Ic sodium-channel blocker.
Uses
Paroxysmal AF (pill-in-pocket or maintenance) and SVT in structurally normal hearts.
Dosing
- Flecainide Rhythm control | Usually 50 mg orally twice daily initially, up to 150 mg twice daily with specialist ECG monitoring. Avoid structural/ischaemic heart disease.
Cardiology: Cardiac Arrhythmias - Stable - no adverse features - is the QRS narrow (under 0.12 s) or broad ? Regular or irregular? Rhythm Treatment Broad, regular (VT or uncertain) Amiodarone 300 mg IV over 10–60 minutes (or as directed by experts); if known SVT with bundle branch block, treat as narrow complex Broad, irregular AF with bundle branch block (treat as AF); …
Acute Medicine: Cardiac arrest, advanced life support and peri-arrest arrhythmias - Broad, irregular | AF with bundle branch block (treat as AF); pre-excited AF (WPW - avoid AV node blockers - no adenosine, digoxin, verapamil, diltiazem - consider cardioversion or flecainide); polymorphic VT / torsades - magnesium 2 g IV over 10 minutes
Acute Medicine: Cardiac arrest, advanced life support and peri-arrest arrhythmias
Side effects
Dizziness, visual disturbance, proarrhythmia, heart failure.
Interactions
Amiodarone, digoxin, beta-blockers, fluoxetine raise levels or effect.
Contraindications and cautions
Structural heart disease, post-MI, heart failure, Brugada syndrome
Monitoring
ECG (QRS), levels
Pregnancy and breastfeeding
Use if essential
Renal and hepatic impairment
Reduce dose in renal impairment
Overdose and reversal
Supportive; sodium bicarbonate
Special advice
Contraindicated after MI or in structural heart disease (CAST trial); give with AV nodal blocker in AF.
More from the textbook: uses, cautions and other points
- Ic | Strong sodium channel block - flecainide , propafenone | AF cardioversion and "pill in the pocket", SVT; avoid in structural or ischaemic heart disease (increased death - CAST trial); can turn AF into flutter with 1:1 conduction - give with an AV nodal blocker
Cardiology: Anatomy Physiology and Pharmacology - Flecainide | Class Ic; avoid in structural or ischaemic heart disease; give with AV nodal blocker.
Cardiology: Anatomy Physiology and Pharmacology - Flecainide: avoid in structural heart disease; amiodarone: thyroid, lung, liver, skin, eyes.
Cardiology: Anatomy Physiology and Pharmacology - Antiarrhythmic maintenance: Selected use of beta blockers, flecainide, dronedarone, sotalol or amiodarone according to heart disease, QT, renal function and interactions.
Cardiology: Cardiac Arrhythmias - Phase 0 - rapid depolarisation: fast sodium channels open (blocked by class I antiarrhythmics - flecainide, lidocaine).
Cardiology: Anatomy Physiology and Pharmacology - AF turned into fast flutter with 1:1 conduction on a new drug | Flecainide without an AV nodal blocker
Cardiology: Anatomy Physiology and Pharmacology - Onset clearly under 48 hours: Can be cardioverted - electrically, or with flecainide (no structural or ischaemic heart disease) or amiodarone (structural disease). Give heparin first.
Cardiology: Cardiology Emergencies - Flecainide Recent-onset AF | Pharmacological cardioversion only if no structural or ischaemic heart disease.
Cardiology: Cardiology Emergencies
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (5 mentions)
- Cardiology: Cardiology Emergencies (2 mentions)
- Cardiology: Cardiac Arrhythmias (4 mentions)
- Cardiology: Cardiomyopathies (1 mention)
- Clinical pharmacology and prescribing: Adverse drug reactions, interactions and drug allergy (1 mention)
- Clinical pharmacology and prescribing: Prescribing in special groups (1 mention)
- Clinical pharmacology and prescribing: Poisoning and overdose (1 mention)
- Acute Medicine: Cardiac arrest, advanced life support and peri-arrest arrhythmias (2 mentions)
- Acute Medicine: The acute medical take (1 mention)
- Clinical Genetics: Cancer genetics and inherited cardiovascular conditions (2 mentions)
- Integrated cardiology chapter (5 mentions)
- 0203 (1 mention)
- Physiology: Nerve, muscle and autonomic systems, exercise, pregnancy and ageing (1 mention)